跳转至内容
Merck
CN

700112P

Avanti

7α-羟基胆甾烯酮-d7

Avanti Research - A Croda Brand

别名:

25,26,26,26,27,27,27-七氘代-7α-羟基-4-胆甾烯-3-酮;111106

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C27H37D7O2
化学文摘社编号:
分子量:
407.68
MDL number:
NACRES:
NA.25
UNSPSC Code:
41141804
Assay:
>99% (TLC)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

7α-羟基胆甾烯酮-d7, Avanti Research - A Croda Brand

description

7α-hydroxy-4-cholesten-3-one-d7

packaging

pkg of 1 × 1 mg (700112P-1mg), pkg of 1 × 10 mg (700112P-10mg), pkg of 1 × 5 mg (700112P-5mg)

manufacturer/tradename

Avanti Research - A Croda Brand

assay

>99% (TLC)

form

powder

shipped in

dry ice

storage temp.

−20°C

General description

7α-羟基-4-胆甾烯-3-酮是胆固醇生化合成胆汁酸的中间体。其前体7α-羟基胆固醇由肝脏胆固醇7α-羟化酶(CYP7A1)从胆固醇中产生。[1]它由酶7α-羟基胆甾-4-烯-3-酮12α-羟化酶代谢为7α,12α-二羟基胆甾-4-烯-3-酮,然后再代谢为胆酸,胆酸是人类主要的原胆汁酸。或者,它可以转化为5β-胆甾烷-3α,7α-二醇,然后转化为鹅去氧胆酸,这是人类的另一种主要原代胆汁酸。血清7α-羟基-4-胆甾烯-3-酮浓度反映胆汁酸合成途径的活性。血清7α-羟基-4-胆甾烯-3-酮值在白天变化,因为胆汁酸合成速率具有昼夜节律。[2] 胆汁酸吸收不良的患者中发现升高值,这可能有助于诊断这种情况,因为高值与低SeHCAT潴留有关。[3] 血清7α-羟基-4-胆甾烯-3-酮浓度的增加反映了胆汁酸吸收不良引起的胆汁酸损失,或在原发性胆汁酸腹泻中发现的合成增加,与FGF19对CYP7A1的负反馈受损有关。[4]

Biochem/physiol Actions

7α-羟基-4-胆甾烯-3-酮,由酶7α-羟基胆甾-4-烯-3-酮12α-羟化酶代谢为7α,12α-二羟基胆甾-4-烯-3-酮,然后再代谢为胆酸,胆酸是人类主要的初级胆汁酸。或者,它可以转化为5β-胆甾烷-3α,7α-二醇,然后转化为鹅去氧胆酸,这是人类的另一种主要原代胆汁酸。血清7α-羟基-4-胆甾烯-3-酮浓度反映胆汁酸合成途径的活性。血清7α-羟基-4-胆甾烯-3-酮值在白天变化,因为胆汁酸合成速率具有昼夜节律。胆汁酸吸收不良患者中测得的7α-羟基-4-胆甾烯-3-酮值升高。这可能有助于诊断这种情况,因为高值与低75硒高胆酸牛磺酸(SeHCAT)滞留有关。7α-羟基-4-胆甾烯-3-酮在伴有腹泻的肠易激综合征(IBS-D)中水平升高。氘标记的7α-羟基-4-胆甾烯-3-酮(d7-7αC4)用作液相色谱-串联质谱(LC-MS/MS)测量中的内标物。

Packaging

5 mL琥珀色玻璃螺旋盖样品瓶(700112P-1mg)
5 mL琥珀色玻璃螺旋盖样品瓶(700112P-5mg)
5 mL琥珀色玻璃螺旋盖样品瓶(700112P-10mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

存储类别

11 - Combustible Solids

flash_point_f

No data available

flash_point_c

No data available


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M Camilleri et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 21(7), 734-e43-734-e43 (2009-04-17)
Bile acid malabsorption (BAM) is reported in up to 50% of patients with functional diarrhoea and irritable bowel syndrome with diarrhoea (IBS-D). Serum 7alpha-hydroxy-4-cholesten-3-one (7alphaHCO or 7alphaC4), an indirect measurement of hepatic bile acid synthesis, has been validated as a
W Gordon Brydon et al.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 25(6), 319-323 (2011-07-19)
Bile acid malabsorption (BAM) is a recognized cause of watery diarrhea, often diagnosed empirically based on clinical response to cholestyramine. The radionuclide selenium-labelled homocholic acid-taurine whole body retention test is expensive, labour intensive and of limited availability. To report on
The enzymes, regulation, and genetics of bile acid synthesis. Annual review of biochemistry
Russell DW
Annual Review of Biochemistry, 72, 137-174 (2003)
Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea.
Brydon WG, et al.
European Journal of Gastroenterology & Hepatology, 8(2), 117-123 (1996)
Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis.
Galman C, et al.
Gastroenterology, 129(5), 1445-1453 (2005)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持